DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical
company focused on the discovery, development and commercialization of
first-in-class therapies for the treatment of patients with open-angle
glaucoma, retinal diseases and other diseases of the eye today announced
that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer,
will present in a fireside discussion at the 18th Annual
Needham Healthcare Conference on Tuesday, April 9, 2019 at 1:30 p.m.
Eastern Time in New York, NY. Dr. Anido will provide an Aerie overview
and provide a business update.
The fireside discussion will be webcast live and may be accessed by
visiting Aerie’s website at http://investors.aeriepharma.com.
A replay of the webcast will be available for 10 business days.
About Aerie Pharmaceuticals, Inc.
Aerie is an ophthalmic pharmaceutical company focused on the discovery,
development and commercialization of first-in-class therapies for the
treatment of patients with open-angle glaucoma, retinal diseases and
other diseases of the eye. Aerie’s first product, Rhopressa®
(netarsudil ophthalmic solution) 0.02%, a once-daily eyedrop approved by
the U.S. Food and Drug Administration (FDA) for the reduction of
elevated intraocular pressure (IOP) in patients with open-angle glaucoma
or ocular hypertension, was launched in the United States in April 2018.
In clinical trials of Rhopressa®, the most common adverse
reactions were conjunctival hyperemia, corneal verticillata,
instillation site pain, and conjunctival hemorrhage. More information
about Rhopressa®, including the product label, is available
at www.rhopressa.com.
Aerie’s second product for the reduction of elevated intraocular
pressure (IOP) in patients with open-angle glaucoma or ocular
hypertension, Rocklatan™ (netarsudil and latanoprost ophthalmic
solution) 0.02%/0.005%, the first and only fixed-dose combination of
Rhopressa® and the widely-prescribed PGA (prostaglandin
analog) latanoprost, has been approved by the FDA and is expected to be
launched in the United States in the second quarter of 2019. In clinical
trials of Rocklatan™, the most common adverse reactions were
conjunctival hyperemia, corneal verticillata, instillation site pain,
and conjunctival hemorrhage. More information about
Rocklatan™, including the product label, is available at www.rocklatan.com.
Aerie continues to focus on global expansion and the development of
additional product candidates and technologies in ophthalmology,
including for wet age-related macular degeneration and diabetic macular
edema. More information is available at www.aeriepharma.com.
Contacts
Media: Tad Heitmann 949-526-8747; theitmann@aeriepharma.com
Investors:
Ami Bavishi 908-947-3949; abavishi@aeriepharma.com